HCB101 + ramucirumab + paclitaxel

This is a combination regimen consisting of three drugs: HCB101, ramucirumab, and paclitaxel. - **HCB101** is a novel Fc-based fusion protein targeting the SIRPα-CD47 pathway, intended to block the "don't eat me" signal that protects tumor cells from phagocytosis. It is being developed as an immunotherapy for advanced solid tumors[3][5][7]. - **Ramucirumab** is a monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis, thereby reducing tumor blood supply. - **Paclitaxel** is a taxane-class chemotherapeutic agent that stabilizes microtubules, thereby blocking cell division; it is used in multiple solid tumors including breast, ovarian, lung, and gastric cancers[2][4][6][8]. This combination is under investigation in a Phase Ib/IIa trial for the treatment of advanced solid tumors, aiming to leverage distinct and potentially complementary mechanisms—macrophage-mediated anti-tumor activity (HCB101), anti-angiogenesis (ramucirumab), and cytotoxicity against rapidly dividing tumor cells (paclitaxel)[1][9].

Other names

paclitaxelramucirumabHCB101HCB-101HCB 101